- Email: [email protected]
5180738 Fumagillol derivatives and pharmaceutical compositions thereof
New Patents
5180590 PROCESS FOR THE PREPARATION OF ANTIINFLAMMATORY PHARMACEUTICAL AGENTS WITH AN IBUPROFEN BASE, WITH ELIMINATION, IN SOLUTION, OF THE BITTER TASTE, BURNING OF THE THROAT AND INTESTINAL TOXICITY Marl Carcano, Massim Costa, Vezia, Switzerland assigned to Aesculapius-Pharma S A Anti-inflammatory pharmaceutical compositions with an ibuprofen base which eliminate the bitter taste, the burning in the throat and the topical toxicity at the level of the intestinal wall when their effervescent aqueous solutions are taken. The proportions among the main ingredients of each dose are the following: ibuprofen, 200 to 800 mg or ibuprofen sodium salt, 221.3 to 885.2 mg; sodium bicarbonate, 2.100 to 8.402 g; and citric acid, 0.450 to 1.800 g.
ix
an alkoxycarbonyl group, which may optionally be substituted or (10) a phenoxycarbonyl group, which may optionally be substituted; or a salt thereof. The compound (I) has a strong angiogenesis inhibitory activity.
5180748 AVARONE AND ITS PHARMACEUTICAL COMPOSITIONS AND USE AS AN ANTIVIRAL AGENT Werner E G Muller, Rudolf K Zahn, Eckart Eich, Wiesbaden Biebrich, Federal Republic Of Germany assigned to Merz+ Co GmbH & Co The antitumor and antiviral compound avarone, a process for its production, pharmaceutical compositions containing said compound, and a method of combating susceptible viruses and tumors therewith, are disclosed.
5182113 5180738 FUMAGILLOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF Shoj Kishimoto, Takeshi Fujita, Takarazuka, both of, Japan assigned to Takeda Chemical Industries The present invention is related to a compound of the formula See Patent for Chemical Structure wherein R1 is a 2-methyl-l-propenyl or isobutyl group which may be substituted and R2 is (1) a substituted alkanoyl group, (2) a substituted aroyl group having at least one substituent selected from the group consisting of C2o6 alkyl, amino, halogen, hydroxyl, lower alkoxy, cyano, carbamoyl and carboxyl, (3) an aromatic heterocycle-carbonyl, which may optionally be substituted, (4) a carbamoyl group, which may optionally be substituted, (5) an alkyl group, which may optionally be substituted, (6) a benzenesulfonyl group, which may optionally be substituted, (7) an alkylsulfonyl group, which may optionally be substituted, (8) a sulfamoyl group, which may optionally be substituted, (9)
FACTOR XA INIBITOR FROM LEECH AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Meir Rigbi, Craig M Jackson, Jerusalem, MI, Israel assigned to Bio-Technology General Corp A novel anticoagulant/modulator factor isolated from the saliva of the medicinal leech Hirudo medicinalis, specifically inhibiting bovine Xa factor but not inhibiting bovine thrombin.
5182261 MODIFIED TRANSFORMING GROWTH FACTOR ALPHA OLIGOPEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF James P Tam assigned to The Rockefeller University
5180590 PROCESS FOR THE PREPARATION OF ANTIINFLAMMATORY PHARMACEUTICAL AGENTS WITH AN IBUPROFEN BASE, WITH ELIMINATION, IN SOLUTION, OF THE BITTER TASTE, BURNING OF THE THROAT AND INTESTINAL TOXICITY Marl Carcano, Massim Costa, Vezia, Switzerland assigned to Aesculapius-Pharma S A Anti-inflammatory pharmaceutical compositions with an ibuprofen base which eliminate the bitter taste, the burning in the throat and the topical toxicity at the level of the intestinal wall when their effervescent aqueous solutions are taken. The proportions among the main ingredients of each dose are the following: ibuprofen, 200 to 800 mg or ibuprofen sodium salt, 221.3 to 885.2 mg; sodium bicarbonate, 2.100 to 8.402 g; and citric acid, 0.450 to 1.800 g.
ix
an alkoxycarbonyl group, which may optionally be substituted or (10) a phenoxycarbonyl group, which may optionally be substituted; or a salt thereof. The compound (I) has a strong angiogenesis inhibitory activity.
5180748 AVARONE AND ITS PHARMACEUTICAL COMPOSITIONS AND USE AS AN ANTIVIRAL AGENT Werner E G Muller, Rudolf K Zahn, Eckart Eich, Wiesbaden Biebrich, Federal Republic Of Germany assigned to Merz+ Co GmbH & Co The antitumor and antiviral compound avarone, a process for its production, pharmaceutical compositions containing said compound, and a method of combating susceptible viruses and tumors therewith, are disclosed.
5182113 5180738 FUMAGILLOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF Shoj Kishimoto, Takeshi Fujita, Takarazuka, both of, Japan assigned to Takeda Chemical Industries The present invention is related to a compound of the formula See Patent for Chemical Structure wherein R1 is a 2-methyl-l-propenyl or isobutyl group which may be substituted and R2 is (1) a substituted alkanoyl group, (2) a substituted aroyl group having at least one substituent selected from the group consisting of C2o6 alkyl, amino, halogen, hydroxyl, lower alkoxy, cyano, carbamoyl and carboxyl, (3) an aromatic heterocycle-carbonyl, which may optionally be substituted, (4) a carbamoyl group, which may optionally be substituted, (5) an alkyl group, which may optionally be substituted, (6) a benzenesulfonyl group, which may optionally be substituted, (7) an alkylsulfonyl group, which may optionally be substituted, (8) a sulfamoyl group, which may optionally be substituted, (9)
FACTOR XA INIBITOR FROM LEECH AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Meir Rigbi, Craig M Jackson, Jerusalem, MI, Israel assigned to Bio-Technology General Corp A novel anticoagulant/modulator factor isolated from the saliva of the medicinal leech Hirudo medicinalis, specifically inhibiting bovine Xa factor but not inhibiting bovine thrombin.
5182261 MODIFIED TRANSFORMING GROWTH FACTOR ALPHA OLIGOPEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF James P Tam assigned to The Rockefeller University